SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA),…
Ann Arbor, MI, March 13, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational and educational purposes only and…
JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…
Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized…
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around…
March 12, 2026 21:03 ET | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia…
March 12, 2026 20:30 ET | Source: Indivior Pharmaceuticals Inc. RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals,…
TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has…
March 11, 2026 19:21 ET | Source: Mesoblast Limited NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05…